目的 探讨注射用丹参多酚酸对发病48 h～14 d的缺血性脑卒中患者的疗效及对患者血脂蛋白相关性磷脂酶A₂（Lp-PLA₂）及氧化修饰型低密度脂蛋白（ox-LDL）的影响。方法 选择2020年1月—2022年6月安阳市人民医院收治的发病48 h～14 d入院的260例缺血性脑卒中患者，按照治疗方案不同分为对照组和试验组，每组各130例，两组均给予缺血性脑卒中的常规治疗，对照组在常规治疗基础上给予注射用血塞通（冻干），每次400 mg加入0.9%氯化钠注射液250 mL，静脉滴注，每天1次；试验组在对照组基础上给予注射用丹参多酚酸，每次取0.13 g加入0.9%氯化钠注射液250 mL，静脉滴注，每天1次。两组疗程均为14 d。比较两组临床疗效，分别于治疗前及治疗14 d后采用美国国立卫生研究院卒中量表（NIHSS）评分量表进行神经功能缺损评估，采用日常生活能力量表（ADL）评分进行日常生活能力评估，采用改良Rankin量表（mRS）评分评价神经功能恢复情况，治疗前及治疗14 d后测定两组患者血浆Lp-PLA₂及血清ox-LDL水平。观察治疗期间两组患者不良反应发生情况。结果 试验组总有效率为93.85%，显著高于对照组的87.69%（P＜0.05）。治疗前两组NIHSS、mRS、ADL评分比较，差异均无统计学意义（P＞0.05）；治疗14 d后两组NIHSS、mRS评分均较本组治疗前显著降低（P＜0.05），且试验组显著低于对照组（P＜0.05）；治疗后，两组ADL评分均较本组治疗前显著升高（P＜0.05）；且试验组显著高于对照组（P＜0.05）。治疗前两组Lp-PLA₂及ox-LDL水平比较，差异均无统计学意义（P＞0.05）；在治疗14 d后两组Lp-PLA₂及ox-LDL水平均较本组治疗前显著降低（P＜0.05），且试验组显著低于对照组（P＜0.05）。治疗期间，两组均未发生明显不良反应。结论 注射用丹参多酚酸能有效降低发病48 h～14 d的缺血性脑卒中患者血Lp-PLA₂及ox-LDL水平，能够改善临床症状，提高生活质量，且安全性好。

Objective To investigate the therapeutic effect of Salvianolic Acid for Injection on cerebral ischemic stroke patients from 48 h to 14 d after onset, and the effect on lipoprotein related phospholipase A₂ (Lp-PLA₂) and oxidized low-density lipoprotein (ox-LDL). Methods From January 2020 to June 2022, 260 patients with cerebral ischemic stroke admitted to Anyang People's Hospital from 48 hours to 14 days after onset were selected. According to different treatment schemes, they were divided into a control group and a experimental group, with 130 cases in each group. Both groups were given conventional treatment for ischemic stroke. Patients in the control group were given Xuesaitong for Injection (freeze-dried) on the basis of conventional treatment, with 400 mg of 0.9% Sodium Chloride Injection 250 mL added each time, intravenous drip, once a day. Patients in the experimental group were given Salvianolic Acid for Injection on the basis of the control group, 0.13 g was taken each time and 250 mL of 0.9% Sodium Chloride Injection was added, intravenous drip once a day. Both groups of treatments lasted for 14 days. The clinical efficacy of two groups was compared, the National Institutes of Health Stroke Scale (NIHSS) was used to assess neurological deficits before and 14 days after treatment. The Activities of Daily Living scale (ADL) was used to assess daily living abilities. The Modified Rankin Scale (mRS) was used to evaluate neurological recovery. Plasma Lp-PLA₂ and serum ox-LDL levels were measured before and 14 days after treatment in both groups of patients. The occurrence of adverse reactions in both groups of patients was observed during the treatment period. Results The total effective rate of the experimental group was 93.85%, significantly higher than 87.69% of the control group (P＜0.05). There was no statistically significant difference in NIHSS, mRS, and ADL scores between the two groups before treatment (P＞0.05). After 14 days of treatment, the NIHSS and mRS scores of both groups were significantly reduced compared to before treatment in same group (P＜0.05), and the experimental group was significantly lower than the control group (P＜0.05). After treatment, the ADL scores of both groups significantly increased compared to before treatment in same group (P＜0.05), and the experimental group was significantly higher than the control group (P＜0.05). There was no statistically significant difference in the levels of Lp-PLA₂ and ox-LDL between the two groups before treatment (P＞0.05). After 14 days of treatment, the levels of Lp-PLA₂ and ox-LDL in both groups were significantly reduced compared to before treatment in same group (P＜0.05), and the experimental group was significantly lower than the control group (P＜0.05). During the treatment period, neither group experienced any significant adverse reactions. Conclusion Salvianolic Acid for Injection can effectively reduce the levels of Lp-PLA₂ and ox-LDL in blood of cerebral ischemic stroke patients from 48 hours to 14 days after onset, improve clinical symptoms, improve quality of life, and have good safety.

R972